Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C5721002 – Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Recurrent or Metastatic Cervical Cancer
2023-503813-31-01Phase 3Completed
- Sponsor
- Seagen Inc.
- Start
- Dec 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of tisotumab vedotin in cervical cancer (mCC) (2 arms), sponsored by Seagen Inc. Primary endpoint: Overall Survival. Started Dec 2023; status: completed.
02
Drugs
tisotumab vedotin
03
Conditions
cervical cancer (mCC)
Beyond the preview
Go deeper on 2023-503813-31-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503813-31-01.